Cyclacel Pharmaceuticals Inc. News
Biotech movers: Shire rises on encouraging angioedema results
Also up early Thursday: Bellicum and Novocure.
Moleculin Biotech gets good verbal OK from FDA which should cut time to phase 1/2 trial down
The Texas-based biotech raised just $9 million in an unorthodox IPO earlier this year, but FDA move should slice months off the time it takes to complete phase 2 trials.
Cyclacel stock runs on momentum rocket fueled by 'Dumb & Dumber' optimism
Shares of biotech micro-cap Cyclacel Pharmaceuticals have doubled in price in the past 10 days. Call it the Lloyd Christmas effect.
Here's Why Cyclacel Pharmaceuticals (CYCC) Stock Is Surging Today
Cyclacel Pharmaceuticals (CYCC) stock is soaring on Monday afternoon as Tang Capital revealed a passive stake in the company.
Cyclacel pharmaceuticals (cycc) stock pops, h.c. wainwright bullish
H.C. Wainwright analysts are bullish on Cyclacel Pharmaceuticals (CYCC) ahead of the company's acute myeloid leukemia study results.
5 Stocks Ready for Breakouts
These stocks are ready to break out and trade higher from current levels.
3 Stocks Under $10 to Trade for Breakouts
These under-$10 stocks are within range of triggering breakout trades.
5 Stocks Under $10 Set to Soar: Venaxis, McDermott and More
These under-$10 stocks are setting up to break out and trade higher from current levels.
Billionaires Got Burned by These Six Struggling Stocks in 2014
Last year was better for some billionaires than it was others. Bill Ackman’s theme song? 'All I Do Is Win.' Carl Icahn’s? 'Maybe Next Year.' Six stocks that really hurt.
Biotech Stock Mailbag: Vanda, Onconova, Catalyst Pharma, Sarepta
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Breaking News
Wells Fargo Stock Lower On Report of Major Mortgage Market Retreat
Wells Fargo could be looking at a major reduction in its once market-leading mortgage business, Bloomberg reported over the weekend.
Oil Prices Slide Below $90 A Barrel As China Demand Fades, U.S. Output Rises
Surging U.S. output, set against fading demand from China, as global oil prices on the back foot again Monday and adding further downward pressure to domestic gas prices.
Turquoise Hill Stock Plunges After Rejecting $2.7 Billion Rio Tinto Buyout Offer
“Oyu Tolgoi is an attractive tier one asset, and we remain highly focused on and optimistic about its transformation into one of the world’s great copper mines," Turquoise Hill said.
Over 1.7 Million Fords And Lincolns Are At Risk Of Being Recalled
The National Highway Transit Safety Administration received over 50 complaints over brake hose ruptures.